Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAREON-5: BI 764532 in Relapsed/Refractory SCLC and Other Neuroendocrine Carcinomas
NCT05882058Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2023
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of obrixtamig in small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC) and large cell neuroendocrine carcinoma (LCNEC) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Objective Response up to 27 months and Treatment-Emergent Adverse Events up to 27 months. Started Oct 2023; status: recruiting.
02
Drugs
obrixtamig
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on NCT05882058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05882058.